Form 8-K - Current report:
SEC Accession No. 0001683168-25-000583
Filing Date
2025-01-30
Accepted
2025-01-29 19:12:40
Documents
14
Period of Report
2025-01-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cnbx_8k.htm   iXBRL 8-K 26462
2 CONVERTIBLE PROMISSORY NOTE cnbx_ex1001.htm EX-10.1 83044
  Complete submission text file 0001683168-25-000583.txt   301608

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnbx-20250124.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cnbx-20250124_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnbx-20250124_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_8k_htm.xml XML 3471
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

EIN.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 8-K | Act: 34 | File No.: 000-52403 | Film No.: 25570655
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)